Enanta Pharmaceuticals Inc
ENTA7.035USD
-0.075-1.05%
交易中 （美东）报价延迟15分钟
150.39M总市值
亏损市盈率 TTM
关于 Enanta Pharmaceuticals Inc 公司
Enanta Pharmaceuticals, Inc. 是一家临床阶段的生物技术公司。该公司从事小分子药物的发现和开发，重点是病毒学和免疫学的适应症。该公司的临床项目专注于呼吸道合胞病毒 (RSV)，其早期免疫学管线旨在通过针对 2 型免疫反应的关键驱动因素（包括受体酪氨酸激酶 (KIT) 和 STAT6 抑制）来开发炎症性疾病的治疗方法。该公司有两种针对 RSV 的临床阶段候选产品，分别是泽利卡帕韦和 EDP-323。该公司发现的蛋白酶抑制剂 Glecaprevir 是治疗慢性丙型肝炎病毒 (HCV) 感染的治疗方案之一，由 AbbVie 在多个国家以商品名 MAVYRET（美国）和 MAVIRET（美国以外）（glecaprevir/pibrentasvir）销售。该公司还拥有针对 SARS-CoV-2 和乙肝病毒的病毒学开发项目。
公司简介
公司代码ENTA
公司名称Enanta Pharmaceuticals Inc
上市日期Mar 21, 2013
CEODr. Jay R. Luly, Ph.D.
员工数量131
证券类型Ordinary Share
年结日Mar 21
公司地址4 Kingsbury Avenue
城市WATERTOWN
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02472
电话16176070800
网址https://www.enanta.com/
公司代码ENTA
上市日期Mar 21, 2013
CEODr. Jay R. Luly, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Jay R. Luly, Ph.D.
Dr. Jay R. Luly, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
826.73K
+8.19%
Dr. Yat Sun Or, Ph.D.
Dr. Yat Sun Or, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
362.33K
+1.52%
Mr. Brendan Luu
Mr. Brendan Luu
Chief Business Officer
Chief Business Officer
22.95K
+22.24%
Dr. Tara L. Kieffer, Ph.D.
Dr. Tara L. Kieffer, Ph.D.
Chief Product Strategy Officer
Chief Product Strategy Officer
--
--
Mr. Terry C. Vance
Mr. Terry C. Vance
Independent Director
Independent Director
--
--
Mr. Paul J. Mellett, Jr.
Mr. Paul J. Mellett, Jr.
Chief Financial and Administrative Officer
Chief Financial and Administrative Officer
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
Independent Director
Independent Director
--
--
Ms. Kristine Peterson
Ms. Kristine Peterson
Independent Director
Independent Director
--
--
Dr. Lesley Russell
Dr. Lesley Russell
Independent Director
Independent Director
--
--
Mr. Mark G. Foletta
Mr. Mark G. Foletta
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Jay R. Luly, Ph.D.
Dr. Jay R. Luly, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
826.73K
+8.19%
Dr. Yat Sun Or, Ph.D.
Dr. Yat Sun Or, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
362.33K
+1.52%
Mr. Brendan Luu
Mr. Brendan Luu
Chief Business Officer
Chief Business Officer
22.95K
+22.24%
Dr. Tara L. Kieffer, Ph.D.
Dr. Tara L. Kieffer, Ph.D.
Chief Product Strategy Officer
Chief Product Strategy Officer
--
--
Mr. Terry C. Vance
Mr. Terry C. Vance
Independent Director
Independent Director
--
--
Mr. Paul J. Mellett, Jr.
Mr. Paul J. Mellett, Jr.
Chief Financial and Administrative Officer
Chief Financial and Administrative Officer
--
--
收入明细
FY2025Q2
FY2024
FY2024Q2
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
14.93M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Farallon Capital Management, L.L.C.
9.93%
Krensavage Asset Management, LLC
9.90%
The Vanguard Group, Inc.
9.39%
BlackRock Institutional Trust Company, N.A.
8.05%
Millennium Management LLC
6.30%
Other
56.43%
持股股东
持股股东
占比
Farallon Capital Management, L.L.C.
9.93%
Krensavage Asset Management, LLC
9.90%
The Vanguard Group, Inc.
9.39%
BlackRock Institutional Trust Company, N.A.
8.05%
Millennium Management LLC
6.30%
Other
56.43%
股东类型
持股股东
占比
Investment Advisor
35.82%
Hedge Fund
25.06%
Investment Advisor/Hedge Fund
23.43%
Individual Investor
6.69%
Research Firm
2.01%
Bank and Trust
0.30%
Family Office
0.20%
Sovereign Wealth Fund
0.19%
Pension Fund
0.15%
Other
6.14%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
315
20.05M
93.80%
-6.87M
2025Q1
342
20.11M
94.09%
-7.55M
2024Q4
348
21.38M
100.27%
-5.34M
2024Q3
354
22.65M
106.92%
-6.74M
2024Q2
352
23.60M
111.43%
-6.27M
2024Q1
361
24.29M
114.84%
-4.07M
2023Q4
373
21.96M
104.28%
-4.11M
2023Q3
375
22.04M
104.75%
-4.91M
2023Q2
376
21.98M
104.47%
-3.80M
2023Q1
380
21.64M
103.62%
-3.43M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Farallon Capital Management, L.L.C.
2.12M
9.93%
+14.00K
+0.66%
Mar 31, 2025
Krensavage Asset Management, LLC
2.12M
9.9%
-804.00
-0.04%
Mar 31, 2025
The Vanguard Group, Inc.
2.01M
9.39%
+23.27K
+1.17%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.72M
8.05%
+3.27K
+0.19%
Mar 31, 2025
Millennium Management LLC
1.35M
6.3%
-35.34K
-2.56%
Mar 31, 2025
Acadian Asset Management LLC
867.04K
4.06%
+17.61K
+2.07%
Mar 31, 2025
Marshall Wace LLP
850.89K
3.98%
-79.20K
-8.52%
Mar 31, 2025
Luly (Jay R)
826.73K
3.87%
+62.57K
+8.19%
Feb 12, 2025
Stonepine Capital Management, LLC
590.74K
2.76%
+258.84K
+77.99%
Mar 31, 2025
Geode Capital Management, L.L.C.
494.20K
2.31%
+16.97K
+3.56%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Invesco NASDAQ Future Gen 200 ETF
0.57%
iShares Micro-Cap ETF
0.03%
Vanguard US Value Factor ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
Avantis US Small Cap Equity ETF
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
Invesco NASDAQ Future Gen 200 ETF
占比0.57%
iShares Micro-Cap ETF
占比0.03%
Vanguard US Value Factor ETF
占比0.02%
ProShares Ultra Nasdaq Biotechnology
占比0.02%
Avantis US Small Cap Equity ETF
占比0.02%
Invesco Nasdaq Biotechnology ETF
占比0.02%
Invesco RAFI US 1500 Small-Mid ETF
占比0.02%
Global X Russell 2000 ETF
占比0.01%
iShares Russell 2000 Value ETF
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
